HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ariflo (SmithKline Beecham plc).

Abstract
Ariflo (SB-207499) is a phosphodiesterase (PDE)4 inhibitor under development by SmithKline Beecham and in phase III and II clinical trials as a potential treatment for chronic obstructive pulmonary disease (COPD) and asthma, respectively [284490]. It has commenced phase II trials as a treatment for bronchial asthma in Japan [248285,300145]. In February 1999, Merrill Lynch predicted that Ariflo would be launched by the end of 2000 or early 2001 with first year sales of UK pounds sterling 25 million rising to UK pounds sterling 175 million in 2003 [300257,314372]. In February 1999 ABN Amro predicted sales of UK pounds sterling 52 million in 2001 rising to UK pounds sterling 254 million in 2005 [317577,328676].
AuthorsW Brown
JournalIDrugs : the investigational drugs journal (IDrugs) Vol. 2 Issue 9 Pg. 915-24 (Sep 1999) ISSN: 1369-7056 [Print] England
PMID16121306 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: